ES2009486A6 - Procedimiento para prepara la forma de hidrocloruro de 2-(4-(2-furoil)-(2-piperazin)-1-il)-4-amin-6,7-dimetoxiquinazolina - Google Patents

Procedimiento para prepara la forma de hidrocloruro de 2-(4-(2-furoil)-(2-piperazin)-1-il)-4-amin-6,7-dimetoxiquinazolina

Info

Publication number
ES2009486A6
ES2009486A6 ES8700500A ES8700500A ES2009486A6 ES 2009486 A6 ES2009486 A6 ES 2009486A6 ES 8700500 A ES8700500 A ES 8700500A ES 8700500 A ES8700500 A ES 8700500A ES 2009486 A6 ES2009486 A6 ES 2009486A6
Authority
ES
Spain
Prior art keywords
furoyl
piperazin
amino
preparation
crystalline anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8700500A
Other languages
English (en)
Inventor
Helmut Schickaneder
Ingomar Grafe
Kurt Henning Arhens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heumann Pharma GmbH and Co
Original Assignee
Heumann Pharma GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma GmbH and Co filed Critical Heumann Pharma GmbH and Co
Publication of ES2009486A6 publication Critical patent/ES2009486A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR LA FORMA DE HIDROCLORURO DE 2-4-(2-FUROIL) -(2-PIPERAZIN)-1-IL -4-AMIN-6,7-DIMETOXIQUINAZOLINA. EL PROCEDIMIENTO OBJETO DEL INVENTO SE CARACTERIZA PORQUE SE HACE REACCIONAR 2-4-(2-FUROIL)-(2-PIPERAZIN)-1-IL -4-AMINO-6,7-DIMETOXIQUINAZOLINA, ESCALONADAMENTE, EN UNA REACCION DE ACIDO-BASE, EN MEDIO ACUOSO Y A CONTINUACION SE SECA, LA FORMA SECADA, OBTENIDA, DE HIDRATO DE HIDROCLORURO DE 2-4-(2-FUROIL)-(2-PIPERAZIN)-1-IL -4-AMINO-6,7-DIMETOXIQUINAZOLINA SE HACE REACCIONAR EN EL SENO DE METANOL, Y LA RESULTANTE FORMA DE METANOLATO DE HIDROCLORURO DE 2-4-(2- FUROIL)-(2-PIPERAZIN)-1-IL -4-AMINO-6,7-DIMETOXIQUINAZOLINA SE SECA, CON ELIMINACION DE LA PORCION DE METANOL DE CRISTALIZACION. ESTA NUEVA FORMA SE DISTINGUE POR UNA SORPRENDENTE ESTABILIDAD EN ALMACENAMIENTO FRENTE A LAS FORMAS POLIMORFAS CONOCIDAS DEL PRAZOSIN.
ES8700500A 1986-03-21 1987-02-25 Procedimiento para prepara la forma de hidrocloruro de 2-(4-(2-furoil)-(2-piperazin)-1-il)-4-amin-6,7-dimetoxiquinazolina Expired ES2009486A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP86103925A EP0237608B1 (de) 1986-03-21 1986-03-21 Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ES2009486A6 true ES2009486A6 (es) 1989-10-01

Family

ID=8194990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8700500A Expired ES2009486A6 (es) 1986-03-21 1987-02-25 Procedimiento para prepara la forma de hidrocloruro de 2-(4-(2-furoil)-(2-piperazin)-1-il)-4-amin-6,7-dimetoxiquinazolina

Country Status (19)

Country Link
US (1) US4816455B1 (es)
EP (1) EP0237608B1 (es)
JP (1) JPH0662615B2 (es)
KR (1) KR870008875A (es)
AR (1) AR242384A1 (es)
AT (1) ATE72244T1 (es)
AU (1) AU586318B2 (es)
CA (1) CA1240999A (es)
DE (1) DE3683760D1 (es)
DK (1) DK173283B1 (es)
ES (1) ES2009486A6 (es)
GR (1) GR870429B (es)
HU (1) HU200176B (es)
ID (1) ID810B (es)
IE (1) IE59913B1 (es)
IL (1) IL81841A (es)
NZ (1) NZ219644A (es)
PT (1) PT84496B (es)
ZA (1) ZA87966B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US6706705B1 (en) * 1994-11-25 2004-03-16 Nippon Chemiphar Co., Ltd. Quinazoline derivatives
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
SK287928B6 (sk) 1998-06-19 2012-04-03 Teijin Pharma Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20080015240A1 (en) * 2004-11-12 2008-01-17 Mitsuru Teramoto Acid Salt of Benzimidazole Derivative and Crystal Thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
EP0146642B1 (de) * 1983-11-22 1988-01-20 LUDWIG HEUMANN & CO GMBH Verfahren zur Herstellung von 4-Amino-6,7-dimethoxy-2-(4-(furo-2-yl)-piperazin-1-yl)-chinazolin und dessen physiologisch annehmbarer Salze
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Also Published As

Publication number Publication date
ID810B (id) 1996-07-15
JPS62226980A (ja) 1987-10-05
HUT47101A (en) 1989-01-30
IL81841A (en) 1991-06-10
JPH0662615B2 (ja) 1994-08-17
EP0237608A1 (de) 1987-09-23
CA1240999A (en) 1988-08-23
HU200176B (en) 1990-04-28
IL81841A0 (en) 1987-10-20
US4816455B1 (en) 1992-11-24
DK139887A (da) 1987-09-22
US4816455A (en) 1989-03-28
GR870429B (en) 1987-07-13
AU6870787A (en) 1987-09-24
KR870008875A (ko) 1987-10-21
PT84496B (pt) 1989-11-10
IE59913B1 (en) 1994-04-20
DK173283B1 (da) 2000-06-13
DE3683760D1 (de) 1992-03-12
AU586318B2 (en) 1989-07-06
IE870705L (en) 1987-09-21
ATE72244T1 (de) 1992-02-15
EP0237608B1 (de) 1992-01-29
AR242384A1 (es) 1993-03-31
DK139887D0 (da) 1987-03-18
ZA87966B (en) 1987-08-04
PT84496A (de) 1987-04-01
NZ219644A (en) 1989-04-26

Similar Documents

Publication Publication Date Title
MY101891A (en) Novel carbostyril derivative and process for preparing same.
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
AU586318B2 (en) Crystalline, anhydrous ```-form of 2-``4-(2-furoyl)- (2-piperazin)-1-yl``-4-amino-6, 7-dimethoxyquinazoline hydrochloride and a process for its preparation
IL112348A0 (en) 3-Amino-2-phenyl- piperidine and (2s, 3s)-3-amino-2-phenylpiperidine
UA5953A1 (uk) Спосіб отримання похідних сульфонілмочевин
ES8604249A1 (es) Un procedimiento para preparar pseudomonato de calcio cris- talino o un hidrato del mismo
FI890245A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1,4-disubstituoitujen piperidinyylijohdannaisten valmistamiseksi
DE3572807D1 (en) A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use
LV10422A (lv) Jaunie fluor-naftacendioni to glikozetie atvasinajumi un vinu razosanas panemiens
EP0253468A3 (en) Six-membered heterocyclic derivatives of n'substituted-n,n'-diacylhydrazines
ATE42091T1 (de) N-(6-methoxy-5(perfluoralkyl)-1-naphthoyl)-nmethylglycine und ihre thionaphthoylanaloga.
MY103216A (en) Nedocromil calcium and use thereof in treatment of reversible obstuctive airways disease
GR3007079T3 (es)
GR3001691T3 (en) Novel crystalline salts of aryloxy-propanolamines, their preparation and their use
AU640647B2 (en) 3-butenamide derivatives
MX9801133A (es) Agente endoparasiticida a base de didepsipeptidos, nuevos didepsipeptidos y procedimiento para su produccion.
SE8103106L (sv) Forfarande for framstellning av 4a-aryl-oktahydro-1h-2-pyrindiner
HUT45250A (en) Process for producing 5-substituted octahydro-indolysin derivatives and pharmaceutical compositions containing them as active components
CA1268468C (en) PROSTAGLANDIN ANALOGS WITH SUBSTITUTE THIABICYCLOHEPTAN GROUP
EP0187711A3 (en) Octahydroindolizine compounds useful as analgesics
EP0245004A3 (en) Antihypercholesterolemic compounds
GR3019711T3 (en) Spiro-indoline-oxazine compounds with photochromatic and photosensitizing characteristics and the process for their preparation
AU6493990A (en) Anhydrous crystal of 4-carbamoyl-1-beta-d-ribofuranosyl imidazolium-5-oleate
IE840831L (en) 1,4-dihydropyridine derivatives
JPS55154940A (en) 2,3-butanediol ester, its preparation and use

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20110301